You are here

Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna

Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna

Submitted by admin on August 18, 2021 - 10:56am

Source:

Motley Fool

News Tags:

Moderna Therapeutics

Delta COVID-19 variant

Headline:

Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna

snippet:

Johnson & Johnson's vaccine won't capture nearly as much market share as Pfizer and Moderna this year.
The company's vaccine has been at a disadvantage due to a perceived lower efficacy rate.
Its effectiveness against the delta variant could lead to an increase in demand. But is the stock a buy?